BELGRADE, Serbia, June 3 /PRNewswire-FirstCall/ - Hard to Treat
Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced
today that researchers from its Slavica BioChem
(www.slavicabiochem.com) division in Belgrade made a great progress in the
experimental findings to aid in the suppression or ultimately cure
of Multiple Sclerosis which are comparable with investigations of
other MS-Research groups around the world.
In a recent press release posted on May
24, 2010 Abbott, and Biogen Idec. announced enrollment of
the first patient in a global Phase III study evaluating the
efficacy and safety of daclizumab compared to interferon beta-1a
(AVONEX(R)) in patients with relapsing-remitting multiple sclerosis
(RRMS), the most common form of multiple sclerosis (MS), one of the
most common neurological disorders that affects more than 2.5
million people worldwide.
This study is based on investigations of researchers from
University Hospital, Basel,
Switzerland. Dr Ludwig
Kappos, M.D., Head, MS-Research Group, and lead investigator
for the study said: "As shown in previous studies, daclizumab
appears to selectively target immune cells that are thought to
become activated in MS and cause damage to the central nervous
system. Daclizumab is a humanized monoclonal antibody that binds to
CD25, a receptor subunit that is expressed at low levels on resting
T-cells and at high levels on T-cells that are thought to become
activated in response to MS. Daclizumab is believed to work by
selectively targeting these activated T-cells without causing
general T-cell depletion leading to reduction in the number of new
or enlarged MS lesions."
Researchers in Belgrade are
also making progress in suppression of immune response in MS using
another immunomodulatory approach that involved application of
purine nucleoside analogues: Ribavirin (FDA approved drug used in
human clinical practice for 20 years) and Tiazofurin (orphan-drug).
These drugs act primarily by inhibition of Inosine Monophosphate
Dehydrogenase (IMPDH), a rate limiting enzyme in de novo purine
synthesis pathway causing interruption of cell metabolism.
Importantly, this exhaustion of purine pools had a more potent
effect on activated lymphocytes than on the other cell types, since
salvage pathways for the production of guanine nucleosides do not
operate in T- and B cells. In this way, Ribavirin and Tiazofurin
also work by selectively targeting activated T-cells. Prof
Mirjana Stojiljkovic, the leader of
IBISS research team, and Medical Advisor of Slavica BioChem
division said: "We have shown promising results in decreasing
severity of clinical symptoms and duration of MS induced in
experimental animals, and radical reduction of mortality and degree
of disability. Administration of ribavirin and tiazofurin
attenuated proliferation of autoreactive T lymphocytes and their
infiltration into the nervous tissue, and thereby prevented myelin
destruction. Similarly to our colleagues from Switzerland we have observed that the severity
of treatment side effects of used substances was low and
disappeared after cessation of drug application. These results are
encouraging for the future of MS therapy."
For any matters relating to retail investor queries or to send
the company or its IR a message please click on the "INVESTOR
SUPPORT" TAB, or the direct link
http://www.minamargroup.net/helpdesk.
Don't be a victim. Report a stock basher to authorities. The
company is mindful that short sellers, the company competitors and
stock bashers stalk small cap Pink Sheets listed companies with
hidden agendas. Visit http://www.stockbasher.com/ and find out what
criminal and civil actions the US authorities are taking against
web sites and the remedies available to you as an individual
investor. Discover for yourself why and how USA based small businesses and the backbone of
the economy suffer. Stay informed and do not allow entrepreneurs
dreams, innovations, and their access to capital to be thwarted as
"scalpers" and day traders vigorously day in and day out try to
exploit and extinguish US innovation and progress for quick
profits.
Filings for this event are currently being reviewed and will be
filed with Pink Sheets and Client Support section in due course. To
be included in company's email database for press releases,
industry updates, and non-weekly activity in the company that may
or may not be news released, please subscribe or opt in mailer at
http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat
Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provisions under the Private Securities
Litigation Reform Act of 1995. The words or phrases "can be,"
"expects," "may affect," "believed," "estimate," "project," and
similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None
of the information in this filing constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hard to
Treat Diseases, Inc.'s actual results may differ materially from
those anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hard to Treat
Diseases, Inc.'s control. In addition to those discussed in Hard to
Treat Diseases, Inc.'s press releases, public filings, and
statements by Hard to Treat Diseases, Inc.'s management, including,
but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future
operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market
opportunities and, in identifying contracts which match Hard to
Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases, Inc. does not
undertake any obligation to publicly update any forward-looking
statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com; for any corporate
matters, please contact corporate@htdsmedical.com,
www.htdsmedical.com
SOURCE Hard to Treat Diseases